1,911 View 87 Download Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan Ichiro Mizushima, Yusuke Yoshimatsu, Hiroki Kiyohara, Shinya Sugimoto, Tomohisa Sujino, Kaoru Takabayashi, Yohei Mikami, Takanori Kanai Received August 13, 2025 Accepted November 19, 2025 Published online February 11, 2026 DOI: [Epub ahead of print] Abstract PDFSupplementary MaterialPubReaderePub Background/Aims Randomized controlled trials have confirmed the efficacy and safety of mirikizumab, an anti-interleukin-23p19 monoclonal antibody, for moderate-to-severe active ulcerative colitis (UC)
used widely in skin care as a active agent to improve skin tone
All peptides sourced from licensed compounding pharmacies with purity testing
Bioactive lipids were then extracted by mixing 1 mL of culture medium with 2 mL of 10% MeOH-0.1% acetic acid and 10 L of deuterated internal standards (25 ng/mL in ethanol)
